1200133-34-1

1200133-34-1 structure

Name: VCH-916
Chemical Name: potassium,5-(cyclohexen-1-yl)-3-[(4-methoxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylate
CAS Number: 1200133-34-1
Molecular Formula: C₂₆H₃₆KNO₄S
Molecular Weight: 497.732
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2018-12-28 00:53:53
Modify Date: 2024-01-14 11:08:12
VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.IC50 Value: Target: HCVVCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.

Name	potassium,5-(cyclohexen-1-yl)-3-[(4-methoxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylate
Synonyms	S1493_Selleck CS-1224 Potassium 5-(1-cyclohexen-1-yl)-3-{(trans-4-methoxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-2-thiophenecarboxylate VCH 916 2-Thiophenecarboxylic acid, 5-(1-cyclohexen-1-yl)-3-[(trans-4-methoxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-, potassium salt (1:1) VCH-916\|\|VCH 916 VCH-916

Description	VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.IC50 Value: Target: HCVVCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HCV Protease Signaling Pathways >> Anti-infection >> HCV Research Areas >> Infection
References	[1]. Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92 [2]. Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161. [3]. Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703 [4]. Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164 [5]. Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Molecular Formula	C₂₆H₃₆KNO₄S
Molecular Weight	497.732
Exact Mass	497.200226
PSA	97.91000
LogP	5.18590
Storage condition	2-8℃

1200133-34-1	713139-25-4
1001913-13-8	1614262-83-7
1026785-59-0	4121-15-7
1210-83-9	6836-19-7
1026785-55-6	14066-13-8